Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kamel Malek"'
Autor:
Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c141ab9d0ac7d7d5923b5c0a6f03c6
https://hdl.handle.net/10281/411282
https://hdl.handle.net/10281/411282
Autor:
Amer M. Zeidan, Jörg Westermann, Tibor Kovacsovics, Sarit Assouline, Andre C. Schuh, Hee-Je Kim, Gabriela Rodriguez Macias, David Sanford, Marlise R. Luskin, Eytan M. Stein, Kamel Malek, Jiaying Lyu, Mario Stegert, Jordi Esteve
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S255
Autor:
Amer M. Zeidan, Jörg Westermann, Tibor Kovacsovics, Sarit Assouline, Andre C. Schuh, Hee-Je Kim, Gabriela Rodriguez Macias, David Sanford, Marlise R. Luskin, Eytan M. Stein, Kamel Malek, Jiaying Lyu, Mario Stegert, Jordi Esteve
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S125
Autor:
Jordi Esteve, Pierre Fenaux, Jeffrey W. Scott, Hee-Je Kim, Severine Peyrard, Yasushi Miyazaki, Uwe Platzbecker, Fei Ma, Julie Niolat, Valeria Santini, Mario Stegert, Zhijian Xiao, Andre C. Schuh, Kamel Malek, Sabine Hertle, Amer M. Zeidan, Flavia Kiertsman, Jörg Westermann, Aristoteles Giagounidis, Mikkael A. Sekeres
Publikováno v:
Blood. 136:45-46
Background: Therapy options for pts with HR-MDS or AML who are not candidates for intensive chemotherapy (IC) or hematopoietic stem cell transplantation (HSCT) are limited, and clinical outcomes are poor. Novel, effective and tolerable therapies are
Autor:
Kamel Malek, Pierre Fenaux, Amer M. Zeidan, Yasushi Miyazaki, Uwe Platzbecker, Flavia Kiertsman, Julie Niolat
Publikováno v:
Blood. 134:4259-4259
Background and Rationale: Pts with higher-risk (HR; intermediate, high, or very high risk) MDS experience poor outcomes and have limited treatment options as most such pts are older and not candidates for the only potentially curative therapy: alloge
Autor:
Kamel Malek, Michaela Sedova, Sunil Sharma, Josep Tabernero, David P. Ryan, Jin Jin, Salvatore Del Prete, Kimmie Ng, Charles S. Fuchs, Jimmy J. Hwang, Emilio Bajetta, Edward R Arrowsmith
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(14)
Purpose: Dysregulation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is seen in 40% to 60% of patients with colorectal cancer. Everolimus, an oral inhibitor of mTOR, showed efficacy in patients with metastatic colorectal cancers in phase I
Autor:
Srdan Verstovsek, Jacek Lukawy, Jingjin Li, Ulrich Pirron, Bijoyesh Mookerjee, Jean-Jacques Kiladjian, Victor Sandor, Alessandro M. Vannucchi, Shui He, William M. Garrett, Kamel Malek
Publikováno v:
Journal of Clinical Oncology. 30:TPS6643-TPS6643
TPS6643^ Background: PV is a myeloproliferative neoplasm characterized by clonal stem cell proliferation, significant morbidity, shortened life span and possible evolution to myelofibrosis and acute myeloid leukemia. Splenomegaly, debilitating consti
Publikováno v:
In Kinésithérapie, la revue February 2013 13(134):44-44